Taiwan’s Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal with China mainland firm CR Double-Crane. The agreement grants CR Double-Crane a 20-year exclusive license to commercialize Fespixon (ON101), a novel etiology-driven solution designed to regulate macrophages and enhance tissue repair, within the Chinese market. This breakthrough therapy is intended for wound care, with a specific focus on diabetic foot ulcers (DFUs), a segment that represents a significant market opportunity in China, where approximately 8.3 million patients suffer from DFUs .
Fespixon, classified as a Category 1 innovative drug, has demonstrated impressive results in clinical trials, showing a 29.2% increase in sales in the second quarter of 2024, reaching €3.303 billion (USD 3.58 billion). Oneness Biotech has high hopes for the drug’s inclusion in China’s National Reimbursement Drug List (NRDL), which would significantly broaden patient access .
Under the terms of the agreement, CR Double-Crane will make an upfront payment of up to USD 34 million to Microbio (Shanghai), with potential sales milestone payments of USD 13.6 million for each tranche of RMB 1 billion net sales achieved. If annual net sales reach RMB 5 billion, the total payments could exceed USD 100 million .
This strategic partnership not only underscores the potential of Fespixon in the Chinese market but also highlights the growing interest in innovative therapies for DFUs, which have traditionally been challenging to treat effectively. Oneness Biotech and Microbio (Shanghai) are committed to advancing wound care solutions, and this deal is expected to pave the way for further collaborations and market expansions in the future . – Fineline.com
